PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.31
-0.08 (-3.35%)
▼
5d:
-2.12%
30d:
+12.68%
90d:
+0.87%
BUY
HIGH Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
28d
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PLX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: PLX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.31, which is considered slightly high relative to its 30-day fair value range of $2.05 to $2.36. From a valuation perspective, the stock is trading at a premium (Forward PE: 46.2) compared to its historical average (29.4). At these levels, the market is pricing in 16.3% annual earnings growth.
Technical Outlook: Technically, PLX is in a strong downtrend. The price is approaching resistance at $2.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: PLX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+376.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PLX is in a strong downtrend. The price is approaching resistance at $2.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: PLX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+376.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.05 -
$2.36
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.6%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 376.2% below Wall St target ($11.00)
- BULLISH: Expecting earnings turnaround to 16.3% growth with 233.7% revenue growth
Trading Range Analysis
30-Day Trading Range
$2.05 -
$2.36
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.19
(8.4%)
Support & Resistance Levels
Support Level
$1.95
Resistance Level
$2.19
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
46.20
Wall Street Target
$11.00
(+376.2%)
Revenue Growth (YoY)
233.7%
Earnings Growth (YoY)
-1.0%
Profit Margin
20.1%
Valuation Premium vs History
+16.3% premium
PE vs Historical
46.2 vs 29.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+16.3%
(market-implied from PE analysis)
1-Year Target
$2.69
(+16%)
2-Year Target
$3.12
(+35%)
3-Year Target
$3.63
(+57%)
3-Yr Target (if PE normalizes)
(PE: 46→29)
PE COMPRESSION
$2.31
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 46.2, Growth: -74.4%)
$1.68
(+-27%)
Base:
(SPY PE: 21.8, Growth: -74.4%)
$0.79
(-66%)
Bear:
(PE: 18.5, Growth: -74.4%)
$0.67
(-71%)
📈
Valuation based on Current Earnings
Trailing PE: 12.84 | Current EPS (TTM): $0.19
Bull Case
$1.34
(-42%)
Analyst growth -50.0%, PE expands to 14.1
Base Case
$1.22
(-47%)
Market implied -50.0%, PE stable at 12.8
Bear Case
$1.66
(-28%)
Severe decline -20.0%, PE contracts to 10.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 10:58 PM ET
Data refreshes hourly during market hours. Next update: 11:58 PM
Data refreshes hourly during market hours. Next update: 11:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
